Marc Beer: Investing in Biotechnology Companies to Improve

Women’s health worldwide received a boost after Renovia Inc. raised $10 million from venture debt and $32 million from a Series B round of funding. The funds raised will be directed towards developing products for diagnosing and treating pelvic disorders which affect more than 250 million women globally.

 

To raise the mentioned funds, the medtech company called on the services of Ascension Ventures and Perceptive Advisors based in Missouri and New York respectively. The Longwood Fund was one of the earliest investors in Renovia Inc. The investment firm focuses on healthcare companies and also joined the Series B round.

 

Based in Boston, Renovia Inc. is looking to develop and test another four diagnostic and therapeutic devices in addition to a new generation of the Leva device. Leva, the company’s first product, was approved by the FDA in April 2018.

 

In a statement, the CEO of Renovia Inc. said he was happy to have found support in leading healthcare investors interested in treating and improving the lives of women affected by pelvic floor disorders such as urinary incontinence.

 

He added that Renovia Inc. customers would now benefit from new treatment options once the company combines its proprietary and innovative form factors and sensor technologies with a digital platform. The digital platform would eventually lower healthcare costs in the long term since it would drive in-depth knowledge and understanding of pelvic floor disorders.

 

Marc Beer has been working with the development and commercialization of pharmaceutical and biotechnology diagnostics and devices for more than two decades. He is the Co-founder, Chairman, and CEO of Renovia Inc.

 

Before co-founding Renovia Inc., he worked with companies such as ViaCell and Genzyme. At ViaCell Marc Beer was the company’s Founding CEO. Under his leadership for seven years, the firm expanded to more than 300 employees before going public. PerkinElmer eventually purchased the company. ViaCell is a biotechnology company dealing in the processing and storage of umbilical cord blood stem cells to enable the application of human cells as medicine.

 

At Genzyme, Marc Beer was the Vice President of Global Marketing. He was in charge of commercially launching products aimed at addressing rare disease populations across the world. Marc Beer also worked in sales and marketing while at Abbott Laboratories in the pharmaceutical and diagnostic divisions.

 

Other roles Marc Beer has held in the past include serving on the boards of various companies. At Erytech Pharma, he served as a member of the board of directors while at Good Start genetics he served as the Founding Chairman of the board of directors. He was also the chairman of the compensation committee at Good Start.

 

Marc Beer is currently serving as the Founding Chairman of the board of directors at Minerva Neurosciences Inc. He is also serving in the company’s audit and compensation committees as a member and chairman respectively. Marc Beer also serves on several boards of different universities. Learn more: https://blogwebpedia.com/marc-beer-entrepreneurial-spirit-biotech.html#.XHg3cFNKiqQ

Leave a Reply

Your email address will not be published. Required fields are marked *